{"id":"doi:10.1007/s40265-023-01851-2","kind":"article","title":"Lecanemab: First Approval","authors":["Sheridan M. Hoy"],"author_count":1,"year":2023,"published":"2023-03-01","venue":"Drugs","cited_by":144,"doi":"10.1007/s40265-023-01851-2","arxiv_id":null,"nct_id":null,"source_url":"https://doi.org/10.1007/s40265-023-01851-2","archive_url":"https://space-kitty.com/papers/doi:10.1007/s40265-023-01851-2","updated":null,"pmid":"36856953","pmcid":null,"openalex_id":"W4322720275","pdf_url":null,"abstract":null,"abstract_license":null,"license":"cc-by-nc","is_open_access":true,"retracted":false,"peer_reviewed":null,"categories":["Alzheimer's disease research and treatments"],"details":null,"provenance":"openalex","attribution":"Metadata and citation counts: OpenAlex (CC0).","topics":[{"slug":"neurodegeneration","name":"Alzheimer's, Parkinson's & Neurodegeneration","domain_slug":"medicine"}],"cited_in_dossiers":[]}